Brought to you by 
Genomic Health develops Oncotype DX test for breast cancer on Biocartis' Idylla system; prostate cancer added
14 Sep 2020
Executive Summary
Biocartis NV and Genomic Health Inc. agreed to work together to develop an in vitro diagnostic version of Genomic Health’s Oncotype DX Breast Recurrence Score test that will run on Biocartis’ Idylla platform.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genomic Health develops Oncotype DX test for breast cancer on Biocartis' Idylla system; prostate cancer added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice